MSRB3

Across TCGA pan-cancer cohorts, MSRB3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MSRB3 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MSRB3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MSRB3 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUAD, COAD, and UCEC are the cancer types where MSRB3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.098	0.682	<.001	17	view →
COAD	DFS	Median	All	0.261	0.694	.007	10	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	OS	Median	All	1.000	0.777	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MSRB3–LUAD (DFS)

Open the LUAD breakdown →